Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
What factors influence whether you order OncotypeDx in HR+ node negative ILC?
Answer from: Medical Oncologist at Academic Institution
If there is differential ER/PR expression or other high risk features such as pleomorphic features or high grade.
Sign in or Register to read more
6394
Related Questions
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What are your top takeaways in Medical Oncology from SABCS 2024?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
Would you discontinue or dose-reduce tamoxifen in a patient who developed hepatic steatosis?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?